Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement
Top Cited Papers
- 20 June 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 113 (24), 2803-2809
- https://doi.org/10.1161/circulationaha.106.618066
Abstract
Background— Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis. The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown. Methods and Results— We used prospectively collected data from a 19-center study of MI patients to examine the prevalence and predictors of thienopyridine discontinuation 30 days after DES treatment. We then compared the mortality and cardiac hospitalization rates for the next 11 months between those who stopped and those who continued thienopyridine therapy. Among 500 DES-treated MI patients who were discharged on thienopyridine therapy, 68 (13.6%) stopped therapy within 30 days. Those who stopped were older, less likely to have completed high school or be married, more likely to avoid health care because of cost, and more likely to have had preexisting cardiovascular disease or anemia at presentation. They were also less likely to have received discharge instructions about their medications or a cardiac rehabilitation referral. Patients who stopped thienopyridine therapy by 30 days were more likely to die during the next 11 months (7.5% versus 0.7%, P P =0.08; adjusted hazard ratio=1.5; 95% confidence interval=0.78 to 3.0). Conclusions— Almost 1 in 7 MI patients who received a DES were no longer taking thienopyridines by 30 days. Prematurely stopping thienopyridine therapy was strongly associated with subsequent mortality. Strategies to improve the use of thienopyridines are needed to optimize the outcomes of MI patients treated with DES.Keywords
This publication has 30 references indexed in Scilit:
- The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)—Evaluating the impact of myocardial infarction on patient outcomesAmerican Heart Journal, 2006
- Adherence to MedicationThe New England Journal of Medicine, 2005
- Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapyCatheterization and Cardiovascular Interventions, 2005
- What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: A meta-analysisJournal of the American College of Cardiology, 2005
- Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantationJournal of the American College of Cardiology, 2005
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryThe New England Journal of Medicine, 2003
- ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina—Summary ArticleCirculation, 2003
- The PHQ-9Journal of General Internal Medicine, 2001
- Treatment adherence and risk of death after a myocardial infarctionThe Lancet, 1990
- Can simple clinical measurements detect patient noncompliance?Hypertension, 1980